Although CAR-T therapies were mainly provided to be effective in blood cancers rather than solid tumors, the CAR-T therapy of MUC1 for SBA may be developed and further studied to benefit SBA patients. Here, MUC1 is linked to hematopoietic and lymphoid system neoplasm.